Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning. Winston Churchill, address to Parliament, 10 November 1942 A key question is, can ...

Neutralizing antibody levels against the original COVID-19 virus and omicron variants in vaccinated adults tend to decline by at least 15% per month after a single booster shot, a new study using ...

The Pfizer-BioNTech BNT162b2 messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccine was one of the first coronavirus disease 2019 (COVID-19) vaccines that were provided ...

When children living with HIV are injected with neutralizing antibodies, the treatment can suppress cells that contain the virus and are capable of reactivating, an early-stage trial found. Details of ...

Viruses evolve under increased pressure, and new research from The Rockefeller University and University of Massachusetts Medical School in the U.S. suggests our antibodies can as well. The team found ...

The BNT162b2 vaccine was shown to have 95% efficacy against coronavirus disease 2019 (Covid-19). 1 To date, the two-dose vaccine protocol has not been approved in Israel for persons previously ...

Some HIV-1 carriers who have received an early antiretroviral treatment during several years are able to control the virus for a long term after treatment interruption. However, the mechanisms ...